1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Autolus Therapeutics PLC (AUTL)
  7. Financials

AUTL

Autolus Therapeutics PLC
2.07
0.01 (0.49%)
Upgrade to Real-Time

Autolus Therapeutics plc (AUTL) Fundamentals
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
SHARE INFORMATION
Market CapUS$ 361,725,726
Shares Outstanding173,074,510
Float173,074,510
Percent Float100.0%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0.00
Latest Fiscal RevenueUS$ 6,194,000
Latest Fiscal EPSUS$ -1.57
Latest Fiscal Date2022-12-31
DIVIDENDS
Dividend (3 Years)US$ 0.00
Dividend (5 Years)US$ 0.00
Ex Dividend Date-
Dividend RateUS$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions117
Institutional Holdings Date2023-02-28
Institutional Bought Previous 3 Months6,044,591
Institutional Holdings Percent49.3%
Institutional Sold Previous 3 Months1,779,776
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned-
TRADING INFO
52 Week HighUS$ 4.73
52 Week LowUS$ 1.60
52 Week High ChangeUS$ -51.28
21 Day Moving AverageUS$ 1.9652
21 Day Extended Moving AverageUS$ 2.0023
50 Day Moving AverageUS$ 1.9758
50 Day Extended Moving AverageUS$ 2.0274
200 Day Moving AverageUS$ 2.5246
200 Day Extended Moving AverageUS$ 2.6482
10 Day Average Volume550,987
20 Day Average Volume431,267
30 Day Average Volume614,084
50 Day Average Volume583,752
Alpha-0.039752
Beta1.5864
Standard Deviation0.201645
R20.190911
7 Day Price ChangeUS$ 0.19
7 Day Percent Change10.0%
21 Day Price ChangeUS$ 0.23
21 Day Percent Change12.37%
30 Day Price ChangeUS$ 0.06
30 Day Percent Change2.96%
Month to Date Price ChangeUS$ 0.15
Month to Date Percent Change7.73%
Quarter to Date Price ChangeUS$ 0.19
Quarter to Date Percent Change10.0%
180 Day Price ChangeUS$ -0.41
180 Day Percent Change-16.4%
200 Day Price ChangeUS$ -1.21
200 Day Percent Change-36.67%
Year to Date Price ChangeUS$ 0.19
Year to Date Percent Change10.0%

Autolus Therapeutics plc (AUTL) Key Ratios

PROFITABILITY
EBIT Margin-5,723.0%
EBITDA Margin-5,476.2%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
RevenueUS$ 6,194,000
Revenue Per ShareUS$ 0.0358
Revenue (3 Years)US$ -11.66
Revenue (5 Years)US$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.20
Total Debt To Equity0.10
Int Coverage-18.50
Current Ratio9.20
Leverage Ratio1.50
Quick Ratio8.90
Long Term Debt To Capital0.06
VALUATION MEASURES
PE Ratio-1.00
Enterprise ValueUS$ 3,545,725
Price to Sales58.3994
Price to Free Cash-3.00
PE High Last 5 Years-2.80
Price To Book1.20
Price To Cash Flow0.00
PE Low Last 5 Years-42.60
Price to Tangible Book1.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.20
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-34.10
Return on Equity-50.09
Return on Capital-71.48

Autolus Therapeutics plc (AUTL) Profile

PROFILE INFO
Issue TypeAD
SEC Type-
AuditorErnst & Young LLP
CEOChristian Itin
Emplyoees333
Last AuditUQ
CIK0001730463
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address191 Wood Lane
The MediaWorks
London, W12 7FP
Websitehttps://www.autolus.com
Facsimile-
Telephone+44 2038296230
Emaill.crabtree@autolus.com
Your Recent History
NASDAQ
AUTL
Autolus Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20230321 23:39:42